These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36053645)

  • 1. Poisonings with ADHD medication in children under the age of 5 years in Australia: a retrospective study, 2004-2019.
    Arbaeen A; Wheate NJ; Cairns R
    BMJ Paediatr Open; 2022 Mar; 6(1):. PubMed ID: 36053645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paediatric poisoning exposures in schools: reports to Australia's largest poisons centre.
    Ly J; Brown JA; Buckley NA; Cairns R
    Arch Dis Child; 2021 Apr; 106(5):496-500. PubMed ID: 33139351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in self-poisoning and psychotropic drug use in people aged 5-19 years: a population-based retrospective cohort study in Australia.
    Cairns R; Karanges EA; Wong A; Brown JA; Robinson J; Pearson SA; Dawson AH; Buckley NA
    BMJ Open; 2019 Feb; 9(2):e026001. PubMed ID: 30787095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid exposures in children under 5 years of age (2004-2019): A retrospective study of calls to Australia's largest poisons information centre.
    Arbaeen A; Wheate NJ; Cairns R
    J Paediatr Child Health; 2021 Jun; 57(6):883-887. PubMed ID: 33460248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADHD medication overdose and misuse: the NSW Poisons Information Centre experience, 2004-2014.
    Cairns R; Daniels B; Wood DA; Brett J
    Med J Aust; 2016 Mar; 204(4):154. PubMed ID: 26937669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.
    Raman SR; Man KKC; Bahmanyar S; Berard A; Bilder S; Boukhris T; Bushnell G; Crystal S; Furu K; KaoYang YH; Karlstad Ø; Kieler H; Kubota K; Lai EC; Martikainen JE; Maura G; Moore N; Montero D; Nakamura H; Neumann A; Pate V; Pottegård A; Pratt NL; Roughead EE; Macias Saint-Gerons D; Stürmer T; Su CC; Zoega H; Sturkenbroom MCJM; Chan EW; Coghill D; Ip P; Wong ICK
    Lancet Psychiatry; 2018 Oct; 5(10):824-835. PubMed ID: 30220514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of psychostimulant prescribing to children with ADHD in Western Australia: variations in age, gender, medication type and dose prescribed.
    Preen DB; Calver J; Sanfilippo FM; Bulsara M; Holman CD
    Aust N Z J Public Health; 2007 Apr; 31(2):120-6. PubMed ID: 17461001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of long-term ADHD medication use in Australian children.
    Efron D; Mulraney M; Sciberras E; Hiscock H; Hearps S; Coghill D
    Arch Dis Child; 2020 Jun; 105(6):593-597. PubMed ID: 31937570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.
    Mac Avin M; Teeling M; Bennett KE
    BMJ Open; 2020 Apr; 10(4):e035716. PubMed ID: 32327478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
    Harstad E; Shults J; Barbaresi W; Bax A; Cacia J; Deavenport-Saman A; Friedman S; LaRosa A; Loe IM; Mittal S; Tulio S; Vanderbilt D; Blum NJ
    JAMA; 2021 May; 325(20):2067-2075. PubMed ID: 33946100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin and mineral supplement exposures: cases reported to Australia's largest Poisons Information Centre, 2014-2015 to 2018-2019.
    Luckock U; Harnett J; Cairns R
    Br J Nutr; 2021 Dec; 126(12):1788-1793. PubMed ID: 33597065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
    McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC
    BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings.
    Cairns R; Schaffer AL; Ryan N; Pearson SA; Buckley NA
    Addiction; 2019 Jun; 114(6):1026-1034. PubMed ID: 30098227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
    Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
    JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
    Storebø OJ; Pedersen N; Ramstad E; Kielsholm ML; Nielsen SS; Krogh HB; Moreira-Maia CR; Magnusson FL; Holmskov M; Gerner T; Skoog M; Rosendal S; Groth C; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Håkonsen SJ; Aagaard L; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012069. PubMed ID: 29744873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-fold increase in national prevalence rates of attention-deficit/hyperactivity disorder medications for children and adolescents with autism spectrum disorder, attention-deficit/hyperactivity disorder, and other psychiatric disorders: a Danish register-based study.
    Dalsgaard S; Nielsen HS; Simonsen M
    J Child Adolesc Psychopharmacol; 2013 Sep; 23(7):432-9. PubMed ID: 24015896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
    Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric ADHD Medication Exposures Reported to US Poison Control Centers.
    King SA; Casavant MJ; Spiller HA; Hodges NL; Chounthirath T; Smith GA
    Pediatrics; 2018 Jun; 141(6):. PubMed ID: 29784754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of medication by young people with attention-deficit/hyperactivity disorder.
    Sawyer MG; Rey JM; Graetz BW; Clark JJ; Baghurst PA
    Med J Aust; 2002 Jul; 177(1):21-5. PubMed ID: 12088474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.